BACKGROUND & AIMS: Zinc deficiency is implicated in the pathogenesis of human esophageal cancer. In the rat esophagus, it induces cell proliferation, modulates genetic expression, and enhances carcinogenesis. Zinc-replenishment reverses proliferation and inhibits carcinogenesis. The zinc-deficient rat model allows the identification of biological differences affected by zinc during early esophageal carcinogenesis. METHODS: We evaluated gene expression profiles of esophageal epithelia from zinc-deficient and replenished rats vs zinc-sufficient rats using microarray analysis. We characterized the role of the top-up-regulated gene S100A8 in esophageal hyperplasia/reversal and in chemically induced esophageal carcinogenesis in zinc-modulated animals by immunohistochemistry and real-time quantitative polymerase chain reaction. RESULTS: The hyperplastic-deficient esophagus has a distinct expression signature with the proinflammation genes S100 calcium binding protein A8 (S100A8) and A9 (S100A9) up-regulated 57-fold and 5-fold, respectively. Zinc replenishment rapidly restored to control levels the expression of S100A8/A9 and 27 other genes and reversed the hyperplastic phenotype. With its receptor for advanced glycation end products (RAGE), colocalization and overexpression of S100A8 protein occurred in the deficient esophagus that overexpressed nuclear factor kappaBeta p65 and cyclooxygenase-2 (COX-2) protein. Zinc replenishment, but not a COX-2 inhibitor, reduced the overexpression of these 4 proteins. Additionally, esophageal S100A8/A9 messenger RNA levels were associated directly with the diverse tumorigenic outcome in zinc-deficient and zinc-replenished rats. CONCLUSIONS: In vivo zinc regulates S100A8 expression and modulates the link between S100A8-RAGE interaction and downstream nuclear factor kappaBeta/COX-2 signaling. The finding that zinc regulates an inflammatory pathway in esophageal carcinogenesis may lead to prevention and therapy for this cancer.
BACKGROUND & AIMS:Zinc deficiency is implicated in the pathogenesis of humanesophageal cancer. In the rat esophagus, it induces cell proliferation, modulates genetic expression, and enhances carcinogenesis. Zinc-replenishment reverses proliferation and inhibits carcinogenesis. The zinc-deficientrat model allows the identification of biological differences affected by zinc during early esophageal carcinogenesis. METHODS: We evaluated gene expression profiles of esophageal epithelia from zinc-deficient and replenished rats vs zinc-sufficient rats using microarray analysis. We characterized the role of the top-up-regulated gene S100A8 in esophageal hyperplasia/reversal and in chemically induced esophageal carcinogenesis in zinc-modulated animals by immunohistochemistry and real-time quantitative polymerase chain reaction. RESULTS: The hyperplastic-deficient esophagus has a distinct expression signature with the proinflammation genes S100 calcium binding protein A8 (S100A8) and A9 (S100A9) up-regulated 57-fold and 5-fold, respectively. Zinc replenishment rapidly restored to control levels the expression of S100A8/A9 and 27 other genes and reversed the hyperplastic phenotype. With its receptor for advanced glycation end products (RAGE), colocalization and overexpression of S100A8 protein occurred in the deficient esophagus that overexpressed nuclear factor kappaBeta p65 and cyclooxygenase-2 (COX-2) protein. Zinc replenishment, but not a COX-2 inhibitor, reduced the overexpression of these 4 proteins. Additionally, esophageal S100A8/A9 messenger RNA levels were associated directly with the diverse tumorigenic outcome in zinc-deficient and zinc-replenished rats. CONCLUSIONS: In vivo zinc regulates S100A8 expression and modulates the link between S100A8-RAGE interaction and downstream nuclear factor kappaBeta/COX-2 signaling. The finding that zinc regulates an inflammatory pathway in esophageal carcinogenesis may lead to prevention and therapy for this cancer.
Authors: A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt Journal: Nature Date: 2000-05-18 Impact factor: 49.962
Authors: Alexander Hermani; Barbara De Servi; Senad Medunjanin; Philippe A Tessier; Doris Mayer Journal: Exp Cell Res Date: 2005-11-17 Impact factor: 3.905
Authors: K Yoshimatsu; D Golijanin; P B Paty; R A Soslow; P J Jakobsson; R A DeLellis; K Subbaramaiah; A J Dannenberg Journal: Clin Cancer Res Date: 2001-12 Impact factor: 12.531
Authors: Jin Sun; James Liu; Xueliang Pan; Donald Quimby; Nicola Zanesi; Teresa Druck; Gerd P Pfeifer; Carlo M Croce; Louise Y Fong; Kay Huebner Journal: Carcinogenesis Date: 2010-11-19 Impact factor: 4.944
Authors: L Jiao; J R Kramer; L Chen; M Rugge; P Parente; G Verstovsek; A Alsarraj; H B El-Serag Journal: Aliment Pharmacol Ther Date: 2013-08-19 Impact factor: 8.171
Authors: Sonja Skrovanek; Katherine DiGuilio; Robert Bailey; William Huntington; Ryan Urbas; Barani Mayilvaganan; Giancarlo Mercogliano; James M Mullin Journal: World J Gastrointest Pathophysiol Date: 2014-11-15
Authors: Hansjuerg Alder; Cristian Taccioli; Hongping Chen; Yubao Jiang; Karl J Smalley; Paolo Fadda; Hatice G Ozer; Kay Huebner; John L Farber; Carlo M Croce; Louise Y Y Fong Journal: Carcinogenesis Date: 2012-06-10 Impact factor: 4.944
Authors: Cristian Taccioli; Michela Garofalo; Hongping Chen; Yubao Jiang; Guidantonio Malagoli Tagliazucchi; Gianpiero Di Leva; Hansjuerg Alder; Paolo Fadda; Justin Middleton; Karl J Smalley; Tommaso Selmi; Srivatsava Naidu; John L Farber; Carlo M Croce; Louise Y Fong Journal: J Natl Cancer Inst Date: 2015-08-18 Impact factor: 13.506